← Back to Search

Behavioural Intervention

Continued Current Care for High Blood Pressure (HIRREM Trial)

N/A
Waitlist Available
Led By Charles Tegeler, MD
Research Sponsored by Wake Forest University Health Sciences
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline to v3 (4-6 weeks following completion of the intervention for hcc, 8-10 weeks after v1 for ccc).
Awards & highlights

HIRREM Trial Summary

This trial will study the effects of HIRREM on people with Stage 1 Primary Hypertension.

Eligible Conditions
  • High Blood Pressure
  • Dysautonomia
  • Cardiovascular Disease
  • Cardiovascular Risk

HIRREM Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline to v3 (4-6 weeks following completion of the intervention for hcc, 8-10 weeks after v1 for ccc).
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline to v3 (4-6 weeks following completion of the intervention for hcc, 8-10 weeks after v1 for ccc). for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Change From Baseline in Blood Pressure, as Measured by an Automated Oscillometric Blood Pressure Device.
Secondary outcome measures
Change in Baroreflex Sensitivity
Change in Center for Epidemiologic Studies Depression Scale (CES-D)
Change in Drop Stick Reaction Time
+11 more
Other outcome measures
Change in Alcohol Intake Screening (Audit-C)

HIRREM Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Continued Current CareExperimental Treatment2 Interventions
Participants will continue their current care.
Group II: HIRREMActive Control2 Interventions
High-resolution, relational, resonance-based, electroencephalic mirroring (HIRREM) is a novel, noninvasive, closed-loop, brainwave mirroring, acoustic stimulation neurotechnology to support relaxation and auto-calibration of neural oscillations, using auditory tones to reflect brain frequencies in near real time.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
HIRREM
2018
N/A
~460

Find a Location

Who is running the clinical trial?

Wake Forest University Health SciencesLead Sponsor
1,241 Previous Clinical Trials
1,004,232 Total Patients Enrolled
Charles Tegeler, MDPrincipal InvestigatorWake Forest University Health Sciences
3 Previous Clinical Trials
170 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is enrollment for this study open at the moment?

"The available information from clinicaltrials.gov shows that this medical trial has ceased patient recruitment for the time being, having been initially posted on August 8th 2018 and last updated July 28th 2022. However, 1246 other studies are actively searching to enrol participants."

Answered by AI
Recent research and studies
clinicaltrials.govStudy
HIRREM for Stage 1 Primary Hypertension
2018. "HIRREM for Stage 1 Primary Hypertension". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03479697.
~1 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top